Animas(R) Vibe(TM), the First Integrated Offering from Animas Corporation and Dexcom, Inc., Receives European CE Mark Approval

WEST CHESTER, Pennsylvania, June 2, 2011 -

- First CGM-enabled, waterproof insulin pump system now approved in
Europe

Animas Corporation announced today the receipt of CE Mark approval for
Animas(R) Vibe(TM), the first and only continuous glucose monitoring
(CGM)-enabled insulin pump system with Dexcom G4(TM) CGM technology.
Animas(R) Vibe(TM) brings together the unique features of an Animas(R)
insulin pump and the convenience of Dexcom CGM, which is the only sensor
approved for up to seven days of wear.

To view the multimedia assets associated with this release, please click:
multivu.prnewswire.com/mnr/animas/49461/

As a CGM-enabled system, the Animas(R) Vibe(TM) insulin pump functions as
a receiver for the Dexcom G4(TM) Sensor. The system delivers real-time
glucose information, alerts for high and low readings, and glucose trend
information, enabling patients to make more informed decisions to help
control their disease.* Unlike currently available CGM-enabled pump systems,
Animas(R) Vibe(TM) displays glucose trends in colour and is waterproof.**

"The CE Mark approval for Animas(R) Vibe(TM) is a significant milestone
for our R&D program and for people living with diabetes who are seeking
better ways to manage their disease," said Henry Anhalt, D.O., Chief Medical
Officer, Animas Corporation. "Avoiding extreme highs and lows in glucose
levels is crucial to controlling diabetes and reducing the risk of long-term
diabetes complications. Animas(R) Vibe(TM) brings together leading pump and
CGM technology to provide more freedom and flexibility to people living with
diabetes."

Clinical studies have shown that adults aged 25 and older with type 1
diabetes who use CGM therapy to help manage their disease often experience
significant improvements in glucose control.(1) Furthermore, patients who use
insulin pump therapy in combination with CGM obtain lower HbA1c levels
relative to baseline and relative to patients who use multiple daily
injections and self-monitoring of blood glucose.(2)

CGM-enabled systems, like Animas(R) Vibe(TM), provide patients with a
more complete glucose picture (compared to fingersticks alone) - including
customizable high and low alerts and rate-of-change alarms and trends. These
features allow patients to make more informed decisions to help control their
disease.*

"Diabetes is a demanding disease. Companies like Dexcom and Animas work
tirelessly to provide people living with diabetes relief in the day-to-day,
hour-by-hour management that is required with this chronic condition," said
Dr. Anhalt. "By combining high-performance pumping with state-of-the-art CGM
technology, we're able to bring people with diabetes tools to better manage
their disease."

Animas(R) Vibe(TM) marks the first integrated product offering from
Animas Corporation, makers of high-performance insulin pump technology and
Dexcom, Inc., the leader in continuous glucose sensing technologies. Now
approved in Europe, the product will initially be available to people living
with diabetes in the United Kingdom, Germany, France, Italy and Sweden.

    Animas(R) Vibe(TM) offers:

    - The latest technology available from Dexcom - Dexcom G4(TM),
      a tiny, round and flexible sensor with the smallest introducer needle
      as compared to Abbott Freestyle Navigator(R) and Medtronic
      Sof-Sensor(R)
    - Advanced high-contrast colour pump screen technology, that
      displays glucose trends with coloured arrows and lines showing where
      and how fast glucose levels are shifting
    - Dexcom sensor technology approved for up to seven days of wear,
      delivering more days of CGM data than those approved for a shorter
      duration
    - Waterproof durability up to 12 feet (3.6 metres) for 24 hours for
      the insulin pump, with a Dexcom G4(TM) Transmitter that is waterproof
      at 8 feet (2.4 metres) for 24 hours
    - Customizable alarms to indicate high and low glucose levels
      including a hypo-safety alarm fixed at 55 mg/dL (3.1mmol/L)
    - Low basal increment (0.025 U/hr) across all available ranges
      (0.025 U/hr to 25.00 U/hr) for precise dosing
    - Compatibility with Diasend(R) communications software, enabling
      patients to store, review and print both CGM and insulin pump data

The International Diabetes Federation estimates that 285 million people
around the world have diabetes. This accounts for approximately 2.8 million
people in the U.K., 7.5 million in Germany, 3.9 million in Italy, 4.2 million
in France, and 484,400 in Sweden respectively.(3)

About Animas Corporation

As part of the Johnson & Johnson Family of Companies, Animas is dedicated
to creating a world without limits for people with diabetes through a wide
range of products, including Animas(R) Vibe(TM), the OneTouch(R) Ping(R)
Glucose Management System, and the Animas(R) 2020 insulin pump. Animas, from
the Latin word meaning "true inner self or soul," has been committed since
1996 to meeting individual patient needs through the development of
life-performance technology and customer service 24 hours a day, 7 days a
week, 365 days a year. To learn more about Animas, visit
www.animascorp.co.uk/

*A glucose reading must be confirmed with a fingerstick test before
taking action.

** The Animas insulin pump is waterproof up to 3.6 metres for 24 hours.
The Dexcom G4(TM) Transmitter is waterproof at 2.4 metres for 24 hours.

This press release contains "forward-looking statements" as defined in
the Private Securities Litigation Reform Act of 1995. These statements are
based on current expectations of future events. If underlying assumptions
prove inaccurate or unknown risks or uncertainties materialize, actual
results could vary materially from the expectations and projections of Animas
Corporation and/or Johnson & Johnson. Risks and uncertainties include, but
are not limited to, general industry conditions and competition; economic
factors, such as interest rate and currency exchange rate fluctuations;
technological advances and patents attained by competitors; challenges
inherent in new product development, including obtaining regulatory
approvals; domestic and foreign health care reforms and governmental laws and
regulations; trends toward health care cost containment; and increased
scrutiny of the healthcare industry by government agencies. A further list
and description of these risks, uncertainties and other factors can be found
in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the
fiscal year ended January 2, 2011. Copies of this Form 10-K, as well as
subsequent filings, are available online at www.sec.gov, www.jnj.com or on
request from Johnson & Johnson. Animas Corporation nor Johnson & Johnson
undertake to update any forward-looking statements as a result of new
information or future events or developments.

References

(1) New England Journal of Medicine. 2008; 359:1464-76. Continuous
Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. Tamborlane, W.
Beck, R., Buckingham, B: Pgs. 1464-1475

(2) New England Journal of Medicine. 2010; 363:4. Effectiveness of
Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. Bergenstal, R.,
Tamborlane,W., Ahmann, A.: Pgs. 315-318

(3) "IDF Diabetes Atlas" International Diabetes Federation. 11 May 2011.
www.diabetesatlas.org/content/eur-data.

Caroline Pavis, Animas Corporation, +1-610-240-8128, Mobile: +1-610-357-3121, CPavis at its.jnj.com